Sourcing Exosomes in Rhode Island
Licensed Rhode Island practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Rhode Island buyers need their own professional license and NPI; the wholesaler license is the supplier’s obligation, not the purchaser’s.
Rhode Island concentrates everything in one agency. The Board of Pharmacy, the Board of Nursing Registration and Nursing Education, and the Board of Medical Licensure and Discipline all operate inside the Department of Health, so license verification, wholesaler licensing, and complaint history run through a single portal, which makes diligence here simpler than in most states.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Rhode Island? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Rhode Island
ExaVeyra ships to licensed practices in all 50 states, Rhode Island included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Rhode Island professional license in good standing, verifiable through the Department of Health’s license verification portal.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Rhode Island resale certificate through the Division of Taxation if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Rhode Island licenses drug wholesalers through the Department of Health under the pharmacy chapter of the General Laws. Section 5-19.1-13 applies to the owner of each place of business, located within or outside the state, that distributes legend drugs and nonprescription drugs at wholesale in Rhode Island, so an out-of-state distributor shipping in is licensed the same way a local warehouse is. Each license is issued to a specific owner and premises and is not transferable; an ownership or location change voids it. The implementing regulation is titled Pharmacists, Pharmacies, and Manufacturers, Wholesalers, and Distributors. The license sits with the distributor, not with the purchasing practice.
R.I. Gen. Laws § 5-19.1-13; 216-RICR-40-15-1 · Rhode Island Department of Health, Board of Pharmacy
Rhode Island regenerative-medicine law
Rhode Island has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Rhode Island has no statute addressing unapproved regenerative therapy, so federal law is the only layer that applies. What the General Laws do contain is narrower on both sides: chapter 23-16.4 prohibits human cloning, and in 2007 the House passed a resolution creating a commission to study the potential for regenerative medicine research in the state. A cloning ban restricts a laboratory technique and a study commission produces a report; neither authorizes, conditions, or restricts any clinical use of stem cells or related products. Practice in this area is governed by the licensing chapters for physicians, nurses, and physician assistants, and by the boards inside the Department of Health that administer them.
How this applies to exosomes
Rhode Island has not enacted a stem cell authorization law like Florida, Texas, or Georgia, a disclosure law like California, or a documentation statute like Tennessee. Its human cloning ban in chapter 23-16.4 is occasionally raised in this context and is beside the point: it prohibits a reproductive technique and says nothing about cells or tissue products in clinical use. There is accordingly no Rhode Island definition that could be read to cover or exclude acellular extracellular vesicles. Exosome products are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Rhode Island practice
Because nurse practitioners hold independent authority and physician assistants work in collaboration rather than under filed supervision agreements, Rhode Island offers more than one workable structure, and the paperwork burden is light by state standards. The compensating feature is concentration: every license involved, and the wholesaler licenses on the supply side, sits in one department, so a practice can verify its providers and its suppliers through the same portal.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Board of Medical Licensure and Discipline, within the Department of Health, may perform medical acts within their scope and are the source of delegation to staff who do not hold independent authority. |
| NP / APRN | Rhode Island defines advanced practice registered nursing as an independent and expanded scope of nursing in section 5-34-3, with certified nurse practitioners exercising independent assessment, diagnosis, and management. A CNP-led practice evaluates and orders within its own scope rather than under a physician protocol. |
| PA | Physician assistants practice under a collaboration model in chapter 5-54: the PA consults or refers as the patient’s condition, the PA’s competence, and the standard of care indicate, a physician is accessible for consultation at all times, and the degree of collaboration is determined at the practice level. |
| RN | Registered nurses may perform delegated treatments within their scope, under an order from a provider with authority to issue one and after that provider has evaluated the patient. Rhode Island rejoined the Nurse Licensure Compact on January 1, 2024, so multistate RN licenses are recognized. An RN does not diagnose, prescribe, or independently select a treatment. |
Good faith examination
Rhode Island expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Given the independent scope in section 5-34-3, that provider can be a physician or a certified nurse practitioner. Confirm current expectations with the Board of Medical Licensure and Discipline and the Board of Nursing Registration and Nursing Education, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
Rhode Island does not today codify a corporate practice prohibition in the bright-line way Texas or New York do, and professional entities with management services arrangements are the usual structures. The direction of travel matters, though: bills introduced in the 2026 session, S 2459 and H 7721, would codify restrictions on management services organizations, ban straw ownership, and require meaningful physician ownership and control of medical practices. They are pending, not law, and any Rhode Island structure should be built with counsel who is watching them.
Cold chain into Rhode Island
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Rhode Island order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Providence | Providence | Largest market, anchored by the state’s academic medical institutions. |
| Newport | Newport | Coastal market with concierge and aesthetic practices. |
| Warwick | Kent | Central market along the bay, served on the Providence lane. |
| Cranston | Providence | Dense residential market adjoining Providence. |
| East Greenwich | Kent | Smaller affluent market with a growing aesthetic segment. |
- Rhode Island orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Vials arrive frozen with the manufacturer’s handling instructions and the Certificate of Analysis for the lot; follow the insert for storage on arrival.
Practice types we supply in Rhode Island
Rhode Island licensing and verification
Rhode Island Board of Medical Licensure and Discipline (RIDOH)
Sits inside the Department of Health, like every board on this page.
Rhode Island Board of Nursing Registration and Nursing Education (RIDOH)
Rhode Island rejoined the Nurse Licensure Compact on January 1, 2024.
Rhode Island Board of Pharmacy (RIDOH)
Issues the Wholesaler/Manufacturer Distributor licenses on the supply side.
Rhode Island Division of Taxation
Sales tax registration and resale certificates.
Rhode Island sourcing questions
- Does Rhode Island have a stem cell law?
- No. Rhode Island has no stem cell authorization, disclosure, or documentation statute. The General Laws prohibit human cloning in chapter 23-16.4, and a 2007 House resolution created a commission to study regenerative medicine research, but neither authorizes nor conditions any clinical service. Exosome products in Rhode Island are governed by federal law, under which no exosome product is FDA approved for administration to humans.
- Are exosome products FDA approved?
- No exosome product is FDA approved for administration to humans, and the FDA has issued a public safety notification about clinics marketing unapproved exosome products. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot documentation on every vial.
- Can a nurse practitioner practice independently in Rhode Island?
- Yes. Section 5-34-3 defines advanced practice registered nursing as an independent and expanded scope of nursing, with certified nurse practitioners exercising independent assessment, diagnosis, and management. A CNP-led practice evaluates and orders within its own scope, with consultation and referral expected where the patient’s condition calls for it.
- Is Rhode Island changing its corporate practice rules?
- Possibly. Bills introduced in the 2026 session, S 2459 and H 7721, would codify restrictions on management services organizations, ban straw ownership of medical practices, and require meaningful physician ownership and control. They are pending rather than enacted, so today’s position remains uncodified, and any ownership structure is a question for Rhode Island counsel who is tracking them.
- Does my Rhode Island clinic need a wholesaler license to buy exosomes?
- No. The Wholesaler/Manufacturer Distributor license under R.I. Gen. Laws 5-19.1-13 is held by the owner of each place of business, in or outside the state, that distributes drugs at wholesale into Rhode Island, which means the distributor, not the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How long does cold-chain shipping take to Rhode Island?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- R.I. Gen. Laws § 5-19.1-13, licensing of wholesalers (accessed 16 October 2026)
- 216-RICR-40-15-1, Pharmacists, Pharmacies, and Manufacturers, Wholesalers, and Distributors (accessed 16 October 2026)
- Rhode Island Department of Health, pharmacy licensing (accessed 16 October 2026)
- R.I. Gen. Laws § 5-34-3, advanced practice registered nursing definitions (accessed 16 October 2026)
- R.I. Gen. Laws § 5-54-2, physician assistant definitions (accessed 16 October 2026)
- R.I. Gen. Laws ch. 23-16.4, human cloning (accessed 16 October 2026)
- Rhode Island Department of Health, professional licensing (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The field’s current characterization standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page says accompanies every Rhode Island shipment.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: Sets out what an MSC-derived small EV preparation must demonstrate, supporting this page’s description of perinatal MSC-derived exosome source material and its documentation standard.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.